Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AAPG.O
stocks logo

AAPG.O

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast AAPG.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG.O is 48.33 USD with a low forecast of 47.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast AAPG.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG.O is 48.33 USD with a low forecast of 47.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.710
sliders
Low
47.00
Averages
48.33
High
50.00
Current: 32.710
sliders
Low
47.00
Averages
48.33
High
50.00
BTIG
Buy
initiated
$50
2025-11-10
Reason
BTIG
Price Target
$50
2025-11-10
initiated
Buy
Reason
BTIG initiated coverage of Ascentage Pharma with a Buy rating and $50 price target. The firm says Ascentage has a "validated" apoptosis-targeted platform and two late-stage assets, Olverembatinib and Lisaftoclax, to drive sustained commercial growth and valuation upside. BTIG views Ascentage as one of the "most compelling" China-based biopharma stocks. The company is positioned to for "sustainable global relevance" as it transitions from clinical-stage to commercial-scale, the analyst tells investors in a research note.
Piper Sandler
Biren Amin
Overweight
initiated
$48
2025-11-05
Reason
Piper Sandler
Biren Amin
Price Target
$48
2025-11-05
initiated
Overweight
Reason
Piper Sandler analyst Biren Amin initiated coverage of Ascentage Pharma with an Overweight rating and $48 price target. The company's two approved assets in China are now under evaluation in the U.S., the analyst tells investors in a research note. Piper projects $1.9B and $1B in peak risk-adjusted global revenues for olverembatinib and lisaftoclax, respectively.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ascentage Pharma Group International (AAPG.O) is -80.40, compared to its 5-year average forward P/E of -18.73. For a more detailed relative valuation and DCF analysis to assess Ascentage Pharma Group International 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-18.73
Current PE
-80.40
Overvalued PE
-2.98
Undervalued PE
-34.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-50.65
Current EV/EBITDA
-527.42
Overvalued EV/EBITDA
26.03
Undervalued EV/EBITDA
-127.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
40.32
Current PS
243.50
Overvalued PS
94.19
Undervalued PS
-13.54
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AAPG.O News & Events

Events Timeline

(ET)
2025-08-17
21:11:15
Ascentage Pharma receives clearance from U.S. FDA, EMA to conduct GLORA-4
select
2025-07-10 (ET)
2025-07-10
09:36:33
Ascentage Pharma announces China NMPA approval of lisaftoclax
select
2025-07-07 (ET)
2025-07-07
19:34:12
Ascentage Pharma names Dr. Veet Misra as CFO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-10Benzinga
Hasbro Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday

  • Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, providing ratings and price targets for their stocks.

  • Solstice Advanced Materials: RBC Capital's Arun Viswanathan rated Solstice Advanced Materials (SOLS) as Sector Perform with a price target of $50, while shares closed at $47.49.

  • Ascentage Pharma Group: BTIG's Justin Zelin rated Ascentage Pharma (AAPG) as Buy with a price target of $50, with shares closing at $31.73.

  • Super League Enterprise and Hasbro: Aegis Capital rated Super League Enterprise (SLE) as Buy with a price target of $5, and Seaport Global rated Hasbro (HAS) as Buy with a price target of $100, with respective closing prices of $1.18 and $76.70.

[object Object]
Preview
4.0
11-05Benzinga
Docebo Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Wednesday

  • Analyst Coverage Initiations: Oppenheimer's Ken Wong initiated coverage on Docebo Inc. (DCBO) with an Outperform rating and a price target of $35, while shares closed at $24.61.

  • Ascentage Pharma Rating: Piper Sandler's Biren Amin initiated coverage on Ascentage Pharma Group (AAPG) with an Overweight rating and a price target of $48, with shares closing at $33.25.

  • Vanda Pharmaceuticals Rating: B. Riley Securities' Madison El-Saadi initiated coverage on Vanda Pharmaceuticals Inc. (VNDA) with a Buy rating and a price target of $11, while shares closed at $4.35.

  • Market Overview: The article provides a snapshot of various stocks and their recent performance, highlighting analyst opinions and price targets for potential investors.

[object Object]
Preview
6.0
11-05Benzinga
Piper Sandler Begins Coverage of Ascentage Pharma Group with Overweight Rating and Sets Price Target at $48

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences to improve their market performance.

  • Market Winning Tools: The platform provides tools and resources designed to help traders win in the markets every day.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ascentage Pharma Group International (AAPG.O) stock price today?

The current price of AAPG.O is 32.71 USD — it has decreased -4.64 % in the last trading day.

arrow icon

What is Ascentage Pharma Group International (AAPG.O)'s business?

Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.

arrow icon

What is the price predicton of AAPG.O Stock?

Wall Street analysts forecast AAPG.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG.O is 48.33 USD with a low forecast of 47.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ascentage Pharma Group International (AAPG.O)'s revenue for the last quarter?

Ascentage Pharma Group International revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Ascentage Pharma Group International (AAPG.O)'s earnings per share (EPS) for the last quarter?

Ascentage Pharma Group International. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Ascentage Pharma Group International (AAPG.O)'s fundamentals?

The market is revising No Change the revenue expectations for AAPG for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -31.12%.
arrow icon

How many employees does Ascentage Pharma Group International (AAPG.O). have?

Ascentage Pharma Group International (AAPG.O) has 0 emplpoyees as of November 18 2025.

arrow icon

What is Ascentage Pharma Group International (AAPG.O) market cap?

Today AAPG.O has the market capitalization of 12.32B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free